<DOC>
	<DOCNO>NCT01620944</DOCNO>
	<brief_summary>The primary objective study antiretroviral ( ARV ) -naïve Human immunodeficiency virus 1 ( HIV-1 ) ribonucleic acid infected subject compare response rate Week 48 daily regimen Atazanavir ( ATV ) / Ritonavir ( RTV ) HS 300/100 mg combine either one additional drug [ Lamivudine ( 3TC ) 300 mg daily ] 2 additional drug [ Tenofovir/Emtricitabine ( TDF/FTC ) 300/200 mg daily ] .</brief_summary>
	<brief_title>Open-Label Study Comparing Efficacy Safety ATV/RTV+3TC With ATV/RTV+TDF/FTC HIV-Infected , Treatment Naïve Subjects , Followed Treatment With ATV/RTV+3TC</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Signed Written Informed Consent Freely give informed consent must obtain subject prior clinical trial participation , include informed consent screening procedure conduct establish subject eligibility trial A freely give Pharmacokinetics ( PK ) substudy consent form must obtain subset subject participate intensive PK substudy 2 . Target Population Treatmentnaive HIV1infected subject ( &lt; 48 hour ARV allow ) Subjects HIV1 Ribonucleic acid ( RNA ) level ≥ 1000 c/mL screen Subjects Antigenic marker helper/inducer T lymphocytes ( CD4 ) + cell count &gt; 100 cells/mm3 3 . Age Reproductive Status Men woman , 18 year age old ( minimum age determine local regulatory legal requirement ) Women childbearing potential ( WOCBP ) must use highly effective method birth control 8 week last dose investigational product minimize risk pregnancy . WOCBP must follow instruction birth control entire duration study include minimum 30 day dose complete Acceptable method highly effective birth control include : Condom spermicide Diaphragm spermicide Cervical cap spermicide Since acceptable available method contraception vary among different country , participate woman may choose preferred contraceptive method atazanavir AI424494 BMS232632 Clinical Protocol Date : 31012012 33 base physician recommendation . Caution warrant coadministration oral contraceptive ( ethinyl estradiol norethindrone ) Women must negative serum urine pregnancy test [ minimum sensitivity 25 IU/L equivalent unit Human chorionic gonadotropin ( HCG ) ] within 24 hour prior start investigational product Women must breastfeed Sexually active fertile men must use highly effective birth control partner WOCBP 1 . Target Disease Exceptions Subjects HIV1 RNA level ≥500,000 c/mL screen Screening HIV genotype show resistance component study regimen ( ATV , RTV , 3TC , TDF/FTC ) Previously document HIV2 infection 2 . Medical History Concurrent Diseases Acute chronic hepatitis B virus ( HBV ) Acute hepatitis C virus ( HCV ) coinfection Note Chronic coinfection hepatitis C exclusion criterion . Subjects acute hepatitis C may option screen event evolve chronic infection Presence newly diagnose HIVrelated opportunistic infection ( OI ) medical condition require acute therapy time enrollment . Subjects stable maintenance therapy OI may enrol Primary HIV infection History current cardiac disease , define presence arrhythmia , ischemic disease , conduction abnormality include leave bundle branch block ( LBB ) leave anterior fascicular block ( LAFB ) , 2nd 3rddegree atrioventricular block ( AVB ) , cardiac abnormality deem clinically significant investigator . In addition , follow Electrocardiogram ( ECG ) finding exclusionary : PR Interval &gt; 260 msec ( severe 1st degree AV Block ) QRS Interval &gt; 120 msec Moderatetosevere hepatic insufficiency Obstructive liver disease Recent therapy agent significant systemic myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic cytotoxic potential within 3 month study start expect need therapy time enrollment , therapy methadone ribavirin/interferons treatment neurotoxic drug drug affect CYP3A4 Concomitant administration proton pump inhibitor ( PPI ) H2 blocker drug potential interaction investigational product Life expectancy &lt; 1 year accord judgment investigator Active alcohol substance use sufficient , investigator 's opinion , prevent adequate compliance study therapy increase risk develop pancreatitis chemical hepatitis History ongoing psychiatry disorder Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dose requirement 3 . Physical Laboratory Test Findings Screening laboratory analysis show follow abnormal laboratory result : Grade IV glucose Grade IV electrolytes Grade IV transaminases Grade IV hematology Calculated creatinine clearance &lt; 60 mL/min estimate CockcroftGault equation 4 . Allergies Adverse Drug Reaction Hypersensitivity component study drug formulation 5 . Sex Reproductive Status Pregnancy 6 . Other Exclusion Criteria Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>